Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Furosemide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | CA12 | O43570 | 2/20 | 0.76 |
| ▸ | CA1 | P00915 | 2/20 | 0.76 |
| ▸ | CA2 | P00918 | 2/20 | 0.76 |
| ▸ | CA6 | P23280 | 2/20 | 0.76 |
| ▸ | CA5A | P35218 | 2/20 | 0.76 |
| ▸ | CA7 | P43166 | 2/20 | 0.76 |
| ▸ | CA9 | Q16790 | 2/20 | 0.76 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.76 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.76 |
| ▸ | HTR1A | P08908 | 1/20 | 0.76 |
| ▸ | CA4 | P22748 | 1/20 | 0.76 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.76 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.76 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.76 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.76 |
| ▸ | APP | P05067 | 9/20 | 0.60 |
| ▸ | TEX264 | Q9Y6I9 | 1/20 | 0.54 |
| ▸ | AQP1 | P29972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Furosemide SCHEMBL428921 | 0.87 | CISD1 (1.00) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL29406913 | 0.87 | CISD1 (1.00) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL9811 | 0.87 | CISD1 (1.00) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL1109955 | 0.86 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL4308371 | 0.86 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL10867860 | 0.86 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL8392126 | 0.86 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL6751172 | 0.86 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL9183914 | 0.86 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 | |
| Furosemide SCHEMBL2519788 | 0.86 | CISD1 (0.98) | CISD1ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654103-B2 | Skin care formulation | EMBRYOGENESIS PTY LTD | 2023-05-23 | — | — | US | disclosed |
| US-20210330579-A1 | SKIN CARE FORMULATION | EMBRYOGENESIS PTY LTD (AU) | 2021-10-28 | — | — | US | disclosed |
| US-20210322299-A1 | SKIN CARE FORMULATION | EMBRYOGENESIS PTY LTD (AU) | 2021-10-21 | — | — | US | disclosed |
| US-11083687-B2 | Skin care formulation | EMBRYOGENESIS PTY LTD | 2021-08-10 | — | — | US | disclosed |
| US-20200030477-A1 | SYSTEMS, DEVICES, AND METHODS INCLUDING IMPLANTABLE DEVICES WITH ANTI-MICROBIAL PROPERTIES | GEARBOX LLC (US) | 2020-01-30 | — | — | US | disclosed |
| US-10426857-B2 | Systems, devices, and methods including implantable devices with anti-microbial properties | GEARBOX, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190183781-A1 | SKIN CARE FORMULATION | EMBRYOGENESIS PTY LTD (AU) | 2019-06-20 | — | — | US | disclosed |
| EP-3490572-A1 | SKIN CARE FORMULATION | Embryogenesis Pty Ltd (AU) | 2019-06-05 | — | — | EP | disclosed |
| CN-109152800-A | Skin care formulation | 胚胎发育私人有限公司 | 2019-01-04 | — | — | CN | disclosed |
| CN-109069360-A | Skin care formulation | 胚胎发育私人有限公司 | 2018-12-21 | — | — | CN | disclosed |
| US-20100234793-A1 | Systems, devices and methods including infection-fighting and monitoring shunts | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-09-16 | — | — | US | disclosed |
| US-20100234792-A1 | Systems, devices, and methods including infection-fighting and monitoring shunts | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2010-09-16 | — | — | US | disclosed |
| WO-2010098868-A1 | SYSTEMS, DEVICES, AND METHODS INCLUDING INFECTION-FIGHTING AND MONITORING SHUNTS | SEARETE, LLC (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20090318802-A1 | System, devices, and methods for detecting occlusions in a biological subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2009-12-24 | — | — | US | disclosed |
| US-20090292195-A1 | System, devices, and methods for detecting occlusions in a biological subject including spectral learning | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2009-11-26 | — | — | US | disclosed |
| US-20090287076-A1 | System, devices, and methods for detecting occlusions in a biological subject | SEARETE LLC | 2009-11-19 | — | — | US | disclosed |
| US-20090281412-A1 | System, devices, and methods for detecting occlusions in a biological subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2009-11-12 | — | — | US | disclosed |
| US-20090281413-A1 | Systems, devices, and methods for detecting occlusions in a biological subject | SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE | 2009-11-12 | — | — | US | disclosed |
| US-20030215462-A1 | Use of UGT inhibitors to increase bioavailability | EASTMAN CHEMICAL COMPANY | 2003-11-20 | — | — | US | disclosed |
| WO-2003055494-A1 | USE OF UGT INHIBITORS TO INCREASE BIOAVAILABILITY | AVMAX, INC. (US) | 2003-07-10 | — | — | WO | disclosed |